Repurposed agents in the Alzheimer's disease drug development pipeline.

ABSTRACT:

Background

Treatments are needed to address the growing prevalence of Alzheimer's disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the pharmaceutical development process is both time-consuming and costly. Drug repurposing provides an opportunity to accelerate this process by investigating the AD-related effects of agents approved for other indications. These drugs have known safety profiles, pharmacokinetic characterization, formulations, doses, and manufacturing processes.

Methods

We assessed repurposed AD therapies represented in Phase I, Phase II, and Phase III of the current AD pipeline as registered on ClinicalTrials.gov as of February 27, 2020.

Results

We identified 53 clinical tria

SUBMITTER: Bauzon J 

PROVIDER: S-EPMC7433208 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature